Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study

Background: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise causality for a subset of the prostate cancer-metabolite associations using two-sample Mendelian randomization (MR).

Methods: The case-control portion of the study was conducted in nine UK centers with men ages 50-69 years who underwent prostate-specific antigen screening for prostate cancer within the Prostate Testing for Cancer and Treatment (ProtecT) trial. Two data sources were used to appraise causality: a genome-wide association study (GWAS) of metabolites in 24,925 participants and a GWAS of prostate cancer in 44,825 cases and 27,904 controls within the Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium.

Results: Thirty-five metabolites were strongly associated with prostate cancer ( < 0.0014, multiple-testing threshold). These fell into four classes: (i) lipids and lipoprotein subclass characteristics (total cholesterol and ratios, cholesterol esters and ratios, free cholesterol and ratios, phospholipids and ratios, and triglyceride ratios); (ii) fatty acids and ratios; (iii) amino acids; (iv) and fluid balance. Fourteen top metabolites were proxied by genetic variables, but MR indicated these were not causal.

Conclusions: We identified 35 circulating metabolites associated with prostate cancer presence, but found no evidence of causality for those 14 testable with MR. Thus, the 14 MR-tested metabolites are unlikely to be mechanistically important in prostate cancer risk.

Impact: The metabolome provides a promising set of biomarkers that may aid prostate cancer classification.

Citing Articles

Assessing Urinary Para-Hydroxyphenylacetic Acid as a Biomarker Candidate in Neuroendocrine Neoplasms.

de Falco R, Costantini S, Russo L, Giannascoli D, Minopoli A, Clemente O Int J Mol Sci. 2024; 25(22).

PMID: 39596382 PMC: 11594794. DOI: 10.3390/ijms252212317.

Prostate cancer risk biomarkers from large cohort and prospective metabolomics studies: A systematic review.

Lopez-Hernandez Y, Andres-Lacueva C, Wishart D, Torres-Calzada C, Martinez-Huelamo M, Almanza-Aguilera E Transl Oncol. 2024; 51:102196.

PMID: 39580963 PMC: 11625367. DOI: 10.1016/j.tranon.2024.102196.

Blood metabolites mediate the causal relationship between circulating CX3CL1 levels and prostate cancer: A 2-step Mendelian randomization study.

Zhou Y, Chen Z, Guo Z, Gao G, Duan Y, Wang H Medicine (Baltimore). 2024; 103(23):e38433.

PMID: 38847691 PMC: 11155528. DOI: 10.1097/MD.0000000000038433.

Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.

Veras A, Batista V, Correia R, de Almeida Tavares M, Rubira R, Tavares E Sci Rep. 2024; 14(1):9626.

PMID: 38671015 PMC: 11053171. DOI: 10.1038/s41598-024-60138-y.

Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses.

Cui H, Zhang W, Zhang L, Qu Y, Xu Z, Tan Z PLoS Med. 2024; 21(3):e1004362.

PMID: 38489391 PMC: 10980219. DOI: 10.1371/journal.pmed.1004362.

References

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

Mondul A, Moore S, Weinstein S, Mannisto S, Sampson J, Albanes D . 1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics. 2014; 10(5):1036-1041. PMC: 4169990. DOI: 10.1007/s11306-014-0643-0. View

Olama A, Kote-Jarai Z, Berndt S, Conti D, Schumacher F, Han Y . A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014; 46(10):1103-9. PMC: 4383163. DOI: 10.1038/ng.3094. View

Kote-Jarai Z, Easton D, Stanford J, Ostrander E, Schleutker J, Ingles S . Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):2052-61. PMC: 2776652. DOI: 10.1158/1055-9965.EPI-08-0317. View

Huang J, Mondul A, Weinstein S, Koutros S, Derkach A, Karoly E . Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Br J Cancer. 2016; 115(9):1087-1095. PMC: 5117796. DOI: 10.1038/bjc.2016.305. View

Gieger C, Geistlinger L, Altmaier E, de Angelis M, Kronenberg F, Meitinger T . Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008; 4(11):e1000282. PMC: 2581785. DOI: 10.1371/journal.pgen.1000282. View

Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen A, Frikke-Schmidt R, Nordestgaard B . Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2012; 61(4):427-436. DOI: 10.1016/j.jacc.2012.08.1026. View

Osl M, Dreiseitl S, Pfeifer B, Weinberger K, Klocker H, Bartsch G . A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics. 2008; 24(24):2908-14. DOI: 10.1093/bioinformatics/btn506. View

Huang G, Liu X, Jiao L, Xu C, Zhang Z, Wang L . Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer. Eur J Pharmacol. 2014; 729:132-7. DOI: 10.1016/j.ejphar.2014.01.048. View

10.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

11.

Eeles R, Kote-Jarai Z, Olama A, Giles G, Guy M, Severi G . Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009; 41(10):1116-21. PMC: 2846760. DOI: 10.1038/ng.450. View

12.

Kettunen J, Demirkan A, Wurtz P, Draisma H, Haller T, Rawal R . Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun. 2016; 7:11122. PMC: 4814583. DOI: 10.1038/ncomms11122. View

13.

Burgess S, Butterworth A, Thompson S . Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013; 37(7):658-65. PMC: 4377079. DOI: 10.1002/gepi.21758. View

14.

Kelly R, Vander Heiden M, Giovannucci E, Mucci L . Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev. 2016; 25(6):887-906. PMC: 4891222. DOI: 10.1158/1055-9965.EPI-15-1223. View

15.

Pierce B, Burgess S . Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013; 178(7):1177-84. PMC: 3783091. DOI: 10.1093/aje/kwt084. View

16.

Zhou X, Mao J, Ai J, Deng Y, Roth M, Pound C . Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS One. 2012; 7(11):e48889. PMC: 3495963. DOI: 10.1371/journal.pone.0048889. View

17.

Athene Lane J, Donovan J, Davis M, Walsh E, Dedman D, Down L . Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol. 2014; 15(10):1109-18. DOI: 10.1016/S1470-2045(14)70361-4. View

18.

Fewell Z, Davey Smith G, Sterne J . The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol. 2007; 166(6):646-55. DOI: 10.1093/aje/kwm165. View

19.

Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T . Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 2011; 6(9):e24143. PMC: 3168486. DOI: 10.1371/journal.pone.0024143. View

20.

Didelez V, Sheehan N . Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res. 2007; 16(4):309-30. DOI: 10.1177/0962280206077743. View